NDV-01 not checked
Relmada Therapeutics, Inc. · NDV01 intravesical controlled release
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urologic Cancer, Non Muscle Invasive Bladder Cancer
- Main trialPhase 3
- “Study REL-NDV01-303 is a Phase 3, open-label, multi-center study to determine the safety and efficacy of NDV-01 in adult participants with NMIBC. The study will include two cohorts: * Cohort 1: a randomized, open-label, parallel group, multi-center, Phase 3 study evaluating the efficacy and safety of the NDV-01 versus observation in participants with histologically confirmed IR-NMIBC. * Cohort 2: an open-label, multi-center, single-arm Phase 3 study evaluating the efficacy and safety of the NDV-01 in two populations of high-risk NMIBC: * Cohort 2a: will include participants with HR-NMIBC…”In the company’s words, NCT07464145 on ClinicalTrials.gov
- Other names
- NDV01 intravesical controlled release · Gemcitabine and docetaxel
Other drugs for Bladder (Urothelial, Transitional Cell) Cancer
- Cretostimogene GrenadenorepvecCG Oncology, Inc. · Phase 3
- Nogapendekin alfa inbakiceptImmunityBio · Phase 2/3
- TAR-210Johnson & Johnson (Janssen) · Phase 3
- TARA-002Protara Therapeutics · Phase 3
- Alpha1HHamlet Pharma AB · Phase 3
- SasanlimabPfizer · Phase 3
Coming up2
- Nov 2027Phase 2 trial completes · ClinicalTrials.gov
- Dec 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Dec 2029 | A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer | |
| Phase 2Recruiting | Nov 2027 | A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC | |
| Phase 3Withdrawn | 30 Jun 2027 | A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy | |
| Phase 3Withdrawn | 1 Sep 2029 | A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026